Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Orexo AB ( (SE:ORX) ) is now available.
Orexo AB announced positive results from a preclinical study using its AmorphOX technology to develop a powder-based intranasal formulation of semaglutide, a GLP-1 receptor agonist. The study showed that the intranasal formulations achieved significantly higher plasma concentrations and bioavailability compared to oral tablets, suggesting potential for needle-free delivery and improved patient adherence. This advancement could enhance Orexo’s strategic positioning by enabling partnerships to expand the use of this novel delivery method for more efficient treatment options.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
Average Trading Volume: 24,052
Technical Sentiment Signal: Buy
Current Market Cap: SEK689.3M
For a thorough assessment of ORX stock, go to TipRanks’ Stock Analysis page.